No Longer Under The Radar: Aetna Narrows Coverage For Questcor’s Acthar
This article was originally published in The Pink Sheet Daily
Executive Summary
Aetna’s decision to no longer cover Acthar in patients with multiple sclerosis or nephrotic syndrome suggests the cost of covering the high-priced niche drug has grown to the point that it is prompting closer scrutiny; promotional campaign has also drawn government review.